Exclusive Statistical Report on Tumor Ablation Market 2021-2025: Industry to Observe Strong Development by Top Key Players - Boston Scientific, Medtronic, Angiodynamics, Misonix

Global Tumor Ablation Market Synopsis:

The exclusive research report on the Global Tumor Ablation Market 2021-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global Tumor Ablation Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

The Global Tumor Ablation Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Tumor Ablation market size to maintain the average annual growth rate of 0.0756537569326 from $250.0 Million in 2015 to $360.0 Million in 2019, market analysts believe that in the next few years, Tumor Ablation market size will be further expanded, we expect that by 2025, The market size of the Tumor Ablation will reach $650.0 Million.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/287805 .

As per the World Health Organization (WHO), it is projected that around 10-11 million cancer cases will be diagnosed each year globally by 2030. The number of new cancer cases is expected to increase by more than 80% in low-income countries compared to half the rate in high-income countries (40 percent) between 2008 to 2030. Lucrative growth potential in currently available therapeutic options and high demand for minimally- and non-invasive therapies are the factors expected to drive the market in upcoming years.

The most important key factors driving the growth of the Global Tumor Ablation Market are increasing burden of cancer, technological advancements, rapid growth in the number of ablation centers, growing awareness about tumor ablation technique, rising aging population, and various initiatives taken by the government organizations.

Based on the regional analysis, North America is estimated to command the largest share of the global market in 2016, followed by Europe. The large market share of the North American region can be attributed to high prevalence and incidence of major types of cancer in the region, increasing inclination of patients towards minimally invasive procedures for cancer treatment, and increasing government funding for cancer research.

Top Major Key Players in the Global Tumor Ablation Market:

1 Angiodynamics

2 Medtronic

3 Boston Scientific

4 Galil Medical

5 Neuwave Medical

6 Misonix

7 Merit Medical

8 Sonacare Medical

9 EDAP TMS and More………………

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Tumor Ablation Market Report 2021” @ https://www.businessindustryreports.com/buy-now/287805/single .

Product Type Segmentation

1 Radiofrequency (RF) Ablation

2 Microwave Ablation

3 Cryoablation

Industry Segmentation

1 Liver Cancer

2 Lung Cancer

3 Kidney Cancer

Latest Medical Industry News:

Boston Scientific (March 18, 2021) - Boston Scientific Receives FDA Approval for TheraSphere Y-90 Glass Microspheres - Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC). The approval expands access to this life-prolonging therapy for a greater number of patients, which, to date, has been utilized under a humanitarian device exemption (HDE) - an FDA classification which required institutional review board approval and limited the number of patients treated with the therapy per year. TheraSphere is now the only radioembolization technology indicated for the treatment of unresectable HCC in the U.S.

HCC is one of the most prevalent cancers in the world and the most common type of primary liver cancer, with more than half a million new global cases diagnosed annually. The American Cancer Society estimates that approximately 32,000 new cases of HCC will be diagnosed in the U.S. in 2021. It is most often treated through surgery, liver transplantation, chemotherapy or embolization, including both chemoembolization and radioembolization - also commonly referred to as selective internal radiation therapy (SIRT). TheraSphere treatment, a type of SIRT with low toxicity, is comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90), which are delivered directly to liver tumors via catheter and result in minimal exposure to surrounding healthy tissue.

Approval of TheraSphere was based on results from the LEGACY study, designed to evaluate the safety and efficacy of the therapy for the treatment of early and advanced HCC. The study analyzed data from 162 patients and met both primary endpoints of objective response rate and duration of response rate (72.2% at four weeks and 76.1% at six months, respectively). Data demonstrated 100% complete or partial patient response up to two TheraSphere treatments - disappearance of all lesions or greater than or equal to 30% decrease in target lesion diameter - and a 93% overall survival rate in patients with transplant or resection following treatment at three years.

"I am honored to have spearheaded the LEGACY trial in which we found that patients with early and advanced HCC exhibited very high response rates as well as clinically meaningful durations of response and survival, establishing TheraSphere as a standard treatment for this patient population," said Riad Salem, M.D., M.B.A, interventional radiologist at Northwestern Memorial Hospital and principal investigator of the LEGACY trial. "The trial results, which have been accepted for publication in Hepatology, produced one of the most comprehensive databases for TheraSphere, empowering physicians to make informed, data-driven decisions for their patients."

"The FDA approval and the recent NICE recommendation will expand access to TheraSphere, which has demonstrated improvement in both survivability and quality of life through 20 years of clinical trials and real-world outcomes in the more than 70,000 patients globally," said Peter Pattison, president of Interventional Oncology, Peripheral Interventions, Boston Scientific. "We expect to continue to focus our efforts on bringing this treatment to more patients, both by planning a randomized trial to study the combination of TheraSphere and immunotherapy in patients with HCC not eligible for curative treatments, as well as further investigating the therapy for different cancer segments, including prostate and brain."

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/287805 .

Points in Table of Contents:

Global Tumor Ablation Market Report 2021

1 Tumor Ablation Product Definition

2 Global Tumor Ablation Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Tumor Ablation Shipments

2.2 Global Manufacturer Tumor Ablation Business Revenue

2.3 Global Tumor Ablation Market Overview

3 Manufacturer Tumor Ablation Business Introduction

3.1 Angiodynamics Tumor Ablation Business Introduction

3.2 Medtronic Tumor Ablation Business Introduction

3.3 Boston Scientific Tumor Ablation Business Introduction

3.4 Galil Medical Tumor Ablation Business Introduction

3.5 Neuwave Medical Tumor Ablation Business Introduction

3.6 Misonix Tumor Ablation Business Introduction

………………. Request free sample to get a complete Table of Content

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.